Bioprocessing solutions for vaccines
Primarily developed to target infectious diseases, new vaccine concepts are now also focusing on immune-oncology applications. In turn, this is leading to the growing use of processing applications employing primary cells or cell lines.
Our in-depth understanding of how various chemistries perform in cell culture systems are combined with our portfolio of production chemicals, single-use systems, process chromatography media and final fill products to sustain the integrity and activity of the vaccine from upstream production or cell-free synthesis to downstream purification process steps through final fill.
Avantor, delivered by VWR, supplies a broad range of cGMP raw materials, single-use systems and process chromatography media, customized to the specific requirements of both traditional vaccines and emerging technologies, such as mRNA vaccines, viral vector vaccine or recombinant vaccines and helps maintaining the integrity, safety and activity of the vaccine during upstream production to downstream purification and through final fill.
Vaccine manufacturing: COVID-19 and beyond
In this interview, Nandu Deorkar, Vice President of R&D, Biopharma Production at Avantor, shares lessons we can learn from the industry’s historic ramp-up from research to manufacturing.
Vaccines workflow
Avantor J.T.Baker® brand offers the only cGMP manufactured IPTG to ICHQ7 standards, providing biopharma researchers and manufacturers with a solution to help scale recombinant vaccines from research and development to clinical then full scale manufacturing with speed, quality and confidence.
